Edition:
United States

Biotechnology & Medical Research

Page 1

DNA Link signs contract worth 2.15 bln won

Sunday, 12 Feb 2017 08:07pm EST

DNA Link Inc <127120.KQ> :Says it signed a 2.15 billion won contract with Hokkaido System Science Co.,Ltd to provide genome analysis service in Japan.

DNA Link signs contract worth 2.45 bln won

Thursday, 9 Feb 2017 09:37pm EST

DNA Link Inc <127120.KQ> :Says it signed a 2.45 billion won contract with Korea Centers for Disease Control and Prevention to build 2017 Korean genome information system.

MDxHealth awarded ConfirmMDx testing contract by US VA

Wednesday, 8 Feb 2017 01:00am EST

MDxHealth SA :MDxHealth awarded US department of Veterans Affairs (VA) contract for ConfirmMDx testing.

Bachem Holding renews supply contract with AstraZeneca

Tuesday, 7 Feb 2017 12:53am EST

Bachem Holding AG : Renews supply contract with AstraZeneca for the peptide active substance Goserelin .Under the terms of the agreement, AstraZeneca will continue acquiring the peptide active substance Goserelin from Bachem for the next five years.

Doxa signs second distribution agreement in Asia

Thursday, 2 Feb 2017 02:36am EST

Doxa AB : Signs deal in Asia .Has signed second distribution agreement with Galla Dental, this time for sale in Singapore through its sister company SA Dental Supply.

PCI Biotech gets NOK 13.8 mln to further development of PCI for use in vaccination

Friday, 27 Jan 2017 02:00am EST

PCI Biotech Holding ASA : PCI Biotech awarded 13.8 million Norwegian crowns ($1.7 million) from Research Council of Norway to further development of PCI for use in vaccination .Project will be initiated in Q3 2017 and run for three and a half years.

Celltrion signs contract worth 53.25 bln won

Wednesday, 25 Jan 2017 09:23pm EST

Celltrion Inc <068270.KQ> :Says it signed a 53.25 billion won contract with Celltrion Healthcare co.,Ltd, to sell antibody drug.

Celltrion signs 149.10 bln won contract with Celltrion Healthcare

Wednesday, 21 Dec 2016 02:45am EST

Celltrion Inc <068270.KQ> : Says it signs 149.10 billion won contract with Celltrion Healthcare to sell remsima .Says the contract period from Dec. 21 to Dec. 31.

Xbrane Biopharma signs agreement with BioAvenir for Spherotide in Israel

Wednesday, 21 Dec 2016 02:00am EST

Xbrane Biopharma AB : Signs agreement with BioAvenir for sales and marketing of Spherotide in Israel . Has signed distribution agreement with BioAvenir for sales and marketing of Spherotide on Israeli market . Estimates, based on expected price and penetration, that Spherotide has sales potential of about 5 million Swedish crowns ($535,361) annually in Israel .Xbrane and BioAvenir will share profits from sales of Spheritode in Israel and Xbrane will receive license fee of 1 million crowns divided in upfront and milestone payments.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary